IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
D
Pipeline Grade
Financial Position (from SEC Filings)
$202.5M
Cash & Equivalents
$72.1M
Quarterly Burn Rate
8 mo
Est. Cash Runway
$1,889M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-09-01 | Phase1 Readout | — |
| 2026-10-01 | Phase2 Readout | — |
| 2026-11-01 | Phase1 Readout | — |
| 2027-01-01 | Phase2 Readout | — |
| 2027-04-30 | Phase2 Readout | — |
| 2027-05-01 | Phase1 Readout | — |
Active Clinical Trials (17)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05727904 | Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untrea... | PHASE3 | Recruiting | 670 |
| NCT04614103 | Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer | PHASE2 | Recruiting | 170 |
| NCT07288203 | A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma | PHASE2 | Active Not Recruiting | 100 |
| NCT05686226 | E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers | PHASE2 | Recruiting | 20 |
| NCT03449108 | LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC... | PHASE2 | Active Not Recruiting | 30 |
| NCT07288073 | TIL Therapy in cSCC and MCC | PHASE2 | Recruiting | 14 |
| NCT06940739 | A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel | PHASE2 | Recruiting | 42 |
| NCT05361174 | A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Met... | PHASE2 | Recruiting | 53 |
| NCT05639972 | E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers | PHASE2 | Recruiting | 15 |
| NCT06481592 | A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer. | PHASE2 | Recruiting | 60 |
| NCT05483491 | KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer | PHASE1 | Recruiting | 30 |
| NCT05607095 | A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferent... | PHASE1 | Recruiting | 30 |
| NCT05640193 | A Study of LN-144 in People With Metastatic Melanoma to the Brain | PHASE1 | Active Not Recruiting | 10 |
| NCT01937468 | Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease | PHASE1 | Active Not Recruiting | 25 |
| NCT06566092 | Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants | PHASE1 | Active Not Recruiting | 40 |
| NCT07192900 | Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease | PHASE1 | Recruiting | 10 |
| NCT05176470 | Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients | PHASE1 | Active Not Recruiting | 2 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.